Zacks Investment Research on MSN
Novavax grants license for use of Matrix-M adjuvant to Pfizer
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Jan 20 (Reuters) - Novavax said on Tuesday it has entered into a licensing agreement with Pfizer to develop vaccine ...
Hosted on MSN
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda. The vaccine was ...
Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results